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BRIEF REPORT 
SCLEROMYXEDEMA WITH SYSTEMIC INVOLVEMENT MIMICS 
RHEUMATIC DISEASES 
EDWARD J.  FUDMAN, JOSEPH GOLBUS, and KOBERT W. IKE 
Scleromyxedema is an infiltrative skin disease 
produced by hyaluronic acid deposition in the dermis. A 
benign monoclonal gammopathy is usually present. We 
report 2 patients with scleromyxedema and systemic 
illnesses. Both patients had muscle weakness, dys- 
phagia, and weight loss in addition to the skin changes. 
One also had sclerodactyly, telangiectasias, and 
Raynaud’s phenomenon. Scleromyxedema with sys- 
temic involvement may mimic rheumatic diseases. 
Scleromyxedema, also known as papular 
mucinosis or lichen myxedematosus, is an unusual 
connective tissue disease which is characterized by 
infiltrative skin lesions and a monoclonal paraprotein. 
Patients with this disorder rarely have systemic man- 
ifestations ( 1 4 ) .  We report 2 cases of scleromyx- 
edema with systemic features which mimicked rheu- 
matic diseases. 
Case reports. Patient I .  Patient 1, a 45-year-old 
white man, was in excellent health until 1976, when he 
developed dyspnea on exertion. Shortly thereafter, he 
noted the appearance of small white papules over his 
forearms and the extensor surfaces of his fingers, 
tightening of the skin around his hands and face, and 
Raynaud’s phenomenon which was precipitated by 
cold and involved triphasic color changes. The skin 
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lesions were biopsied and interpreted as sclero- 
myxedema. 
Over the next 3 years, the patient was hospital- 
ized twice with severe proximal muscle weakness, 
dysphagia, weight loss, pain and swelling of his fingers 
and wrists, facial and truncal telangiectasias, and 
progressive skin thickening. On both occasions, mus- 
cle enzyme levels were elevated and electromyogra- 
phy (EMG) findings were consistent with inflamma- 
tory myopathy . Pulmonary function studies revealed a 
mild decrease in diffusion capacity. Results of a bar- 
ium swallow were normal. Manometric studies 
showed striated muscle dysfunction with low contrac- 
tion amplitudes in the hypopharynx and upper 
esophagus. A persistent monoclonal IgGh paraprotein 
was identified in his serum. Treatment consisted of 
prednisone, 60 mg/day and melphalan, 2 mg/day; on 
this regimen, his muscle strength returned and his skin 
improved. 
In 1983, the melphalan dosage was reduced to 2 
mg every other day, and the prednisone dosage was 
tapered as well. Since then he has noted a slow 
progression in his skin thickness, which severely limits 
motion about his mouth, fingers, elbows, and knees. 
The papules have spread and coalesced over the malar 
region, the glabella, and around his ears. 
On examination, his skin revealed diffuse thick- 
ening over the upper arms, thighs, chest, and face, 
especially around the ears, mouth, and forehead. The 
skin was not “bound-down,” but was freely movable 
over the subcutaneous tissues. There were extensive 
hard, white papules, 3-6 mm in diameter, over his 
hands, neck, and forehead, and multiple telangi- 
ectasias over his trunk and face (Figure 1). The head, 
eyes, ears, nose, and throat examination results were 
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Figwe 1. Patient I ,  demonstrating telangiectasias, diminished oral 
aperture, and multiple papules over the bridge of the nose. 
within normal limits, except for marked oral dryness 
and severe dental caries. The chest examination re- 
vealed decreased respiratory excursions and diffuse 
dry basilar crackles. Cardiovascular and abdominal 
examination results were normal. Examination of the 
extremities revealed sclerodactyly with flexion 
contractures of the fingers. Nailfold capillary micros- 
copy :showed dilated loops and avascular areas. There 
were no digital telangiectasias or digital pitting scars. 
The right elbow had a 15" flexion contracture. No 
peripheral joint had evidence of active synovitis. A 
neurologic examination, which included muscle 
strength testing, gave normal results. 
Laboratory studies revealed normal values on 
complete blood count (CBC) and platelet count. 
Urinalysis showed I +  protein. The value for blood 
urea nitrogen was 31 mg/dl and the creatinine value 
was 1.4 mg/dl. Creatinine clearance was 53 mliminute. 
The Westergren erythrocyte sedimentation rate (ESR) 
was 66 mmlhour. Serum protein electrophoresis 
showed an IgGh monoclonal spike, though total serum 
IgG levels were normal. Values for creatine kinase, 
aldolase, serum glutamic oxaloacetic transaminase 
(SGOT), serum glutamic pyruvic transaminase 
(SGPT), and total protein were all within normal 
limits. Serum tests for rheumatoid factor, antinuclear 
antibodies (ANA) using rat liver and HEp-2 sub- 
strates, complement levels, cryoglobulins, and double- 
stranded DNA antibodies were all negative or normal. 
The chest radiograph result was normal. A barium 
swallow, which had given normal results 6 years 
earlier, showed diffuse esophageal dysmotility. A bone 
survey revealed no lytic lesions. A bone marrow 
biopsy revealed a slight increase in the number of 
plasma cells, but no other abnormalities. Evaluation 
for Sjogren's syndrome included a Schirmer's test and 
a minor salivary gland biopsy, both of which showed 
normal results. A skin biopsy from the left shoulder 
was diagnostic of scleromyxedema. There were focal 
subepidermal mucinous deposits and increased num- 
bers of dermal fibroblasts. Skin appendages were 
preserved, and there was no increased deposition of 
collagen in the dermis. 
Patient 2. This patient, a 27-year-old black 
man, first noted proximal muscle weakness when in 
1982, during Marine training, he was unable to do 
pullups. While in Korea in the summer of 1983, he had 
difficulty stepping into trucks. Later that summer, he 
developed dysphagia and a diffuse, nonpruritic, 
papular rash over his arms. He was unable to rise from 
a squatting position due to progressive muscle weak- 
ness. In 1985, a facial rash developed, and he com- 
plained of being unable to move his tongue freely. He 
denied the presence of fevers, myalgias, arthralgias or 
arthritis, Raynaud's phenomenon, or dyspnea. 
Physical examination findings were significant 
for diffuse facial edema, with erythema in a malar 
distribution and under the lower lip. There was a fine 
papular rash over the arms, trunk, back, and knees 
(Figure 2). He could not fully open his mouth or 
protrude his tongue. Results of the cardiopulmonary, 
abdominal, and joint examinations were normal. Mus- 
cle bulk was decreased, proximally more than distally. 
Muscle strength was mildly diminished in the shoulder 
and hip girdles with intact distal strength. There was 
no muscle tenderness. 
CBC and urinalysis results were normal. The 
Westergren ESR was 3 mm/hour. Abnormal chemistry 
results included: SGOT, 137 units; SGPT, 162 units; 
BRIEF REPORTS 915 
row, and sural nerve were all normal, without evi- 
dence of infiltrates or  of mucin or amyloid deposits. 
Discussion. Scleromyxedema is a rare disease of 
unknown etiology, in which there is deposition of 
hyaluronic acid within the dermis and, usually, a 
benign monoclonal gammopathy . The deposition of 
hyaluronic acid results in nodular, sclerotic skin 
changes, most commonly involving the face, hands, 
fingers, and extensor surfaces of the extremities. In 
addition, there may be generalized lichenoid erup- 
tions, lichenoid plaques, or discrete papules. If the 
skin becomes diffusely thickened, the disease may 
resemble scleroderma (1-4). 
A monoclonal paraprotein has been found in 
most patients who have scleromyxedema, including 
the 2 reported here. Almost always, it is an IgG with A 
light chains, although K light chains have been re- 
ported as well (5-8). While the paraprotein is antigeni- 
cally homogenous in any given patient, there is no 
evidence for shared idiotypic determinants among 
Figure 2. Arm of patient 2, showing multiple fine papules. 
lactate dehydrogenase, 830 units; and creatine kinase, 
8,400 IU/liter. Serum protein electrophoresis revealed 
a small monoclonal IgGK spike. HEp-2, ANA, VDRL, 
and hepatitis B serologies were all negative. Thyroid 
function was normal. The chest radiographic results 
were normal. During a barium swallow, the patient 
aspirated a large amount of barium, and the study was 
terminated. The hypopharynx and esophagus were 
anatomically normal. Results of manometric studies 
were normal although pharyngeal pressures were bor- 
derline low. An EMG revealed a severe inflammatory 
myopathy with no evidence of neuropathy. 
The skin biopsy showed increased fibroblasts in 
the mid- and deep reticular dermis with diffuse inter- 
stitial deposits of acid mucopolysaccharides; these led 
to a diagnosis of scleromyxedema. Muscle biopsy 
revealed numerous atrophic and hypertrophic fibers 
(types I and 11), with muscle fiber splitting, internal- 
ization of nuclei, and vacuolated fibers. There were 
scattered necrotic fibers, some of which were under- 
going myophagocytosis by macrophages. There was 
evidence of muscle fiber regeneration. No inflamma- 
tow jnfiltrates were Seen (Figure 3)*  stain- 
ing did not reveal increased hyaluronic acid deposition 
in the muscle. Biopsy specimens of liver, bone mar- 
Figure 3. Muscle biopsy from patient 2. Atrophic and hypertrophic 
fibers are seen, with fiber splitting and central nuclei. Arrowhead 
indicates an example of muscle fiber splitting (hematoxylin and 
eosin stained, original magnification x 100). 
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Table 1. Descriptions of myopathy in scleromyxedema* 
Muscle 
Ref. no. Agelsex weakness Muscle evaluation Dysphagia Esophageal studies 
1 1  35iM Proximal CK elevated, EMG myopathy, Yes BS normal 
12 581F Proximal CK elevated, EMG inflamma- Yes Not reported 
biopsy (see text description) 
tory myopathy. biopsy (see 
text description) 
13 39/F Unspecified CK not reported. EMG inflam- Yes BS aperistalsis 




Present report 45/M Proximal CK elevated, EMG inflamma- Yes BS normal (1979), M striated muscle dys- 
function (1979), BS diffuse dysmotility 
(1985) 
Present report 27lM Proximal CK elevated, EMG inflamma- Yes BS aspiration, M borderline low pharyn- 
geal pressures tory myopathy, biopsy (see 
text description) - 
* CK := creatine kinase; EMG = electromyography; BS = barium swallow: M = manometrics. 
indiviiduals (7). Whether the serum paraprotein plays a 
role im the pathogenesis of the disease is still unknown. 
Previous studies have reported that serum from pa- 
tients with scleromyxedema stimulated human fibro- 
blast production. This effect, however, persisted after 
removal of immunoglobulin (9). A more recent study 
by Yaron and coworkers (10) found an inhibitory or no 
effect of scleromyxedema serum on fibroblast prolif- 
eraticin, although the serum did induce a twofold 
increase in hyaluronic acid synthesis and a thirteenfold 
increase in prostaglandin E synthesis, as compared 
with that in controls. This stimulation was inhibited by 
both lhydrocortisone and indomethacin (10). Based on 
these studies and previous work, the authors suggest 
that the factor stimulating hyaluronic acid production 
in patients with scleromyxedema could be mediated 
through prostaglandins. The component of serum re- 
spansible for these effects remains undetermined. 
The diagnosis of scleromyxedema was made in 
both of our patients on the basis of the typical clinical 
appearance of the cutaneous lesions, skin biopsies that 
revealed increased deposition of acid mucopolysac- 
chwide without increased collagen deposition, and the 
presence of IgG paraprotein. While scleromyxedema 
rarely involves organs other than the skin, the 2 
patients presented here had systemic features resem- 
bling rheumatic diseases, in addition to cutaneous 
involvement. Patient 1 had scleroderma-like features 
of tight skin, sclerodactyly, and a decreased oral 
aperture, all of which are commonly seen in 
scleromyxedema. Also, he had systemic features 
which mimicked systemic sclerosis, including 
Raynaud’s phenomenon, dysphagia, telangiectasias, 
myopathy , weight loss, and decreased pulmonary dif- 
fusion capacity. Individually, many of these findings 
have been reported as rare complications of sclero- 
myxedema; however, they have not been reported to 
occur together in the same patient. Patient 2 presented 
with cutaneous features of scleromyxedema and de- 
veloped severe dysphagia, weight loss, and a proximal 
myopathy that was clinically similar to polymyositis. 
Muscle weakness and dysphagia were seen in 
both our patients. Myopathy has been reported in 6 
other patients who had scleromyxedema. The clinical 
manifestations have been described in only 3 of these 
patients (Table 1). Two had proximal muscle weakness 
and the third patient had weakness which was not 
further characterized. All 3 patients had dysphagia. 
Creatine kinase was elevated in 2 patients and not 
reported in the third. An EMG showed electrodiagnos- 
tic evidence of an inflammatory myopathy in 2 patients 
and of myopathy (details not reported) in the third 
(1 1-13). Muscle biopsy descriptions have been re- 
ported in detail for 2 patients. One biopsy demon- 
strated atrophic perifascicular fibers with multiple 
vacuoles and a chronic perivascular inflammatory in- 
filtrate (1 1). Biopsy samples from the second patient 
also demonstrated perifascicular atrophy, involving 
type I1 fibers only, and a necrotizing myopathy . There 
were increased glycogen deposits seen in necrotic and 
vacuolated fibers. Rare inflammatory infiltrates were 
seen (12). It is also noteworthy that, in 1 patient 
studied at autopsy (14), pathologic findings showed 
degeneration and infiltration of lymphocytes in muscle 
tissues. However, hyaluronic acid deposition was not 
found in either the biopsy specimens or the autopsy 
material (1 1,12,14). 
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From our 2 patients and the descriptions of 3 
others in the literature, it appears that scleromyx- 
edema myopathy manifests primarily as painless prox- 
imal muscle weakness and dysphagia. Elevated serum 
muscle enzymes and inflammatory myopathic changes 
on EMG are present. No consistent findings on muscle 
biopsy have been identified thus far. In contrast with 
the marked hyaluronic acid deposition noted in the 
dermis, no deposits have been found in any of the 
muscle biopsy specimens studied. 
Several authors have reported other rheumatic 
features in association with scleromyxedema. Frayha 
(15) has described a patient with scleromyxedema who 
developed an erosive seronegative rheumatoid-like 
arthropathy , carpal tunnel syndrome, sicca complex, 
and sclerodactyly with acrolysis. There have been 8 
additional reports of seronegative rheumatoid arthritis 
in patients with scleromyxedema; 2 patients had ero- 
sive disease. Harris and colleagues (13) reported a 
patient who, like our first patient, had biopsy-proven 
scleromyxedema, sclerodactyly, dysphagia with 
esophageal aperistalsis, diminished diffusion capacity 
on pulmonary function testing, and an inflammatory 
myopathy . The pathogenesis of the systemic findings 
in scleromyxedema remains unknown, since histopath- 
ologic analyses of synovial biopsies and other tissue in 
all of these patients were repeatedly negative for 
mucin deposition. 
As our case reports demonstrate, scleromyx- 
edema, usually considered to be a disease confined to 
the skin, may have systemic features which mimic 
rheumatic diseases such as progressive systemic scle- 
rosis and polymyositis. The diagnosis of scleromyx- 
edema should be suspected in patients who have a 
scleroderma-like illness or myopathy in the presence 
of a papular eruption or a monoclonal paraprotein. 
Skin biopsy findings of increased dermal hyaluronic 
acid deposition without increased collagen deposition 
are diagnostic of the disease. 
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